ArticleFrontiers in neurology
Association between elevated serum amyloid a levels and clinical outcomes in intracerebral haemorrhage: a retrospective study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Following an intracerebral haemorrhage (ICH), secondary brain injury (SBI) occurs, triggering an inflammatory response. Serum amyloid A (SAA) levels, an acute-phase response protein, increase during acute inflammation and tissue damage. While SAA is associated with ICH prognosis, systematic studies investigating its dynamic longitudinal progression and its relationship with bleeding severity remain limited. Materials and methods: In this single-centre, real-world cohort study, we measured SAA levels in 554 ICH patients and 119 healthy controls. Neurological deficit was quantified based on haematoma expansion (HE), the National Institutes of Health Stroke Scale (NIHSS) score, and the Glasgow Coma Scale (GCS) score after ICH. SAA levels were measured within 24 h of admission and on days 3 and 7 after ICH onset in this longitudinal study. Univariate and multivariate logistic regression analyses were performed to determine the independent association between SAA levels and NIHSS and GCS scores. Adjusted logistic regression and receiver operating characteristic (ROC) curves were used to assess the association between HE and SAA levels. Additionally, the role of SAA levels in SBI was evaluated by monitoring their changes within 24 h of admission and on days 3 and 7 after ICH. Results: SAA levels were significantly higher in patients with ICH than in healthy controls (3.1 vs. 2.4 mg/L, Conclusion: Patients with ICH exhibit elevated SAA levels that are associated with prognosis. Dynamic monitoring of these levels indicates that day 3 may be a critical time point for observing changes in SAA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.